Table 2 Retrospective clinical data compared to corresponding patient′s organoid drug sensitivity results.
From: Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids
Clinical results | Organoid results | |
|---|---|---|
Patient 1 | Whipple procedure with an adjuvant round of gemcitabine. Liver metastases emerged and a round of gemcitabine + paclitaxel (otherwise known as gemcitabine + abraxane in clinic) was given right before the patient expired. Total duration was 11 months. | Organoids were most sensitive to a treatment of gemcitabine + paclitaxel |
Patient 2 | Whipple procedure followed by delayed adjuvant round of gemcitabine due to surgical complications. Liver metastases emerged and FOLFIRINOX with dose reduction was administered, before the patient expired. Gemcitabine + paclitaxel was planned, but never administered. Total duration was 16 months. | Organoids were most sensitive to gemcitabine and gemcitabine + 5-FU. |
Patient 3 | Patient received neoadjuvant FOLFIRINOX before the Whipple procedure, followed by an adjuvant round of gemcitabine. Local recurrence and liver metastases emerged. A round of gemcitabine + paclitaxel was administered, but was discontinued due to intolerance before the patient expired. Total duration was 10 months. | Organoids were most sensitive to all gemcitabine-containing therapies |
